Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 2,907 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Binge Eating Disorder
Interventions: Lisdexamfetamine dimesylate, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 39
States / cities: Fort Myers, Florida • Lauderhill, Florida • Leesburg, Florida + 35 more

Conditions: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 83
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more

Conditions: Alzheimer Disease
Interventions: Salvia officinalis (sage); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Health Adult Subjects
Interventions: Omaveloxolone, Moxifloxacin; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Multiple Sclerosis
Interventions: Fingolimod, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,083 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 100
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more

Conditions: ACL Tear, Post Operative Pain
Interventions: Iovera, Celecoxib, Acetaminophen, Oxycodone, Tramadol, Bupivacaine Hydrochloride, Acetaminophen 500Mg Cap; Device · Drug
Lead sponsor: Matthew Varacallo; Other
Eligibility: 15 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: DuBois, Pennsylvania

Conditions: Stress Disorders, Post-Traumatic, Combat Disorders, Sleep Disorders
Interventions: prazosin hydrochloride, placebo; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Seattle, Washington • Tacoma, Washington

Conditions: Subarachnoid Hemorrhage, Aneurysmal
Interventions: EG-1962 (nimodipine microparticles), Enteral Nimodipine; Drug
Lead sponsor: Edge Therapeutics Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 32 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Canagliflozin 300mg/Placebo, Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 5
States / cities: Chula Vista, California • Miramar, Florida • Cincinnati, Ohio + 2 more

Conditions: Perennial Allergic Rhinitis
Interventions: Placebo Nasal Aerosol, Prednisone capsules, Placebo Prednisone Capsules, Beclomethasone dipropionate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: North Dartmouth, Massachusetts • New Braunfels, Texas • San Antonio, Texas

Conditions: Diabetes
Interventions: VI-0521; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more

Conditions: Signs and Symptoms, Digestive
Interventions: probiotic plus fish oil capsule, Fish oil capsule; Dietary Supplement
Lead sponsor: Nutrition 21, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Pembroke Pines, Florida

Conditions: mCRPC
Interventions: Placebo, Senaparib; Drug
Lead sponsor: Impact Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Binghamton, New York

Conditions: Type 2 Diabetes Mellitus, Heart Failure
Interventions: Saxagliptin, Sitagliptin, Placebo to match saxagliptin, Placebo to match sitagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 11
States / cities: Torrance, California • Upland, California • Miami, Florida + 7 more

Conditions: Healthy
Interventions: AMATEA™, Caffeine, Placebo; Dietary Supplement · Other
Lead sponsor: University of Memphis; Other
Eligibility: 18 Years to 40 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Parkinson's Disease
Interventions: Placebo, Tozadenant; Drug
Lead sponsor: Biotie Therapies Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Systemic Lupus Erythematosus
Interventions: Matching placebo, Cenerimod; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Anniston, Alabama • Clearwater, Florida

Conditions: Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions: Estradiol, placebo; Drug
Lead sponsor: TherapeuticsMD; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Obesity, Vascular Dementia, Cognitive Impairment
Interventions: Urolithin A, Placebo; Dietary Supplement · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 40 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Adults With Ulcerative Colitis
Interventions: PRIM-DJ2727, Placebos; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatopulmonary Syndrome
Interventions: Sorafenib, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 7
States / cities: Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota + 4 more

Conditions: Leg Cramps, Nocturnal
Interventions: vitamin d, placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 50 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Interstitial Cystitis, Painful Bladder Syndrome, Bladder Pain Syndrome, Low Dose Naltrexone, Low-dose Naltrexone, Naltrexone
Interventions: low-dose naltrexone, Placebo oral tablet; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 110 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Skokie, Illinois

Conditions: Chronic Idiopathic Constipation
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 93
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 71 more

Search by objective public record fields.

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients

A TQTc Study for Omaveloxolone

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Impact of Opioid Avoidance Protocol for ACL Reconstruction

Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)

Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults

Clinical Trial Evaluating the Viability of L. Casei + Fish Oil Capsules

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

Impact of AMATEA™️ on Physiological Measures and Gaming Performance in Active Gamers: a Placebo Controlled, Double-blind, Randomized Study

Study to Evaluate SYN115 in Parkinson's Disease

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

Urolithin A Supplementation in Middle-aged Adults With Obesity

Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis

Sorafenib for Hepatopulmonary Syndrome

Vitamin D for Painful Nocturnal Leg Cramps

IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone

Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation